Received May 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 273H3 | IM / LL |
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 1 | Z005856 | SC / OT |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 1 | Z016561 | SC / OT |
Pt. onset with fever on 5/8/26, max temp. 103, 101.6-101.8 for past 2 days prior to being seen in ER on 5/12/26. Maculopapular rash started on 5/12/26 on trunk, back and some on forehead. Pt. seen for these symptoms first in urgent care then in ER in 5/12/26. Provider had concern for possible measles and contacted local county health department.
none
none
none
none
Measles PCR testing and MeVA PCR testing approved by local health jurisdiction. NP swab collected on 5/12/26, positive measles PCR and inconclusive MeVa results reported on 5/14/26. After consultation with State Department of Health and Infection Prevention team, County Health Department determined rash to be attributed and consistent with recent receipt of the MMR vaccine.